How would Larry's treatment course align with the recent updates to the NCCN guidelines?
The recent NCCN guidelines take into account the new approved drugs for pancreatic cancer. Remember, historically, we were limited to one drug, that being gemcitabine. Now we have two drugs that have been approved over the last 5 years, that being nab-paclitaxel/abraxane and also, more recently, Onivyde, or nanoparticle liposomal irinotecan.
This patient was treated with abraxane/gemcitabine, then went on to Onivyde and then MM-398, the liposomal irinotecan, and then went on to FOLFOX chemotherapy. The NCCN guidelines recommend that if you’re given gemcitabine-based treatment in the frontline, that second-line, you go on to a clinical trial, or you go on to Onivyde and then MM-398. It’s a category one recommendation. This patient was treated very strictly along those guidelines.
Metastatic Pancreatic Cancer: Case 1
Larry D, a 62-year-old, presented to his primary care physician with persistent pain in his epigastric region, which persists throughout the night. Within the past 2 years, he has developed diabetes and experienced considerable weight loss with signs of depression.
Larry went on to receive the combination of nab-paclitaxel and gemcitabine as frontline therapy for 5 months:
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen